Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
AbbVie
(NY:
ABBV
)
159.62
-7.67 (-4.58%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
59
60
Next >
$1000 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
November 06, 2023
Via
Benzinga
3 Spectacular High-Yield Dividend Stocks to Buy in November
November 05, 2023
Income investors should find plenty to like with these stocks.
Via
The Motley Fool
Looking for a Lifetime of Passive Income? 2 Top Dividend Stocks to Buy and Hold Forever
November 04, 2023
Dividend stocks can cushion your portfolio in times of market trouble.
Via
The Motley Fool
Check Out What Whales Are Doing With ABBV
November 03, 2023
Via
Benzinga
Is AbbVie Stock a Buy Now?
November 03, 2023
It just had a brutal quarter, and it might have a couple more on the way.
Via
The Motley Fool
Top 5 Dividend Stocks In My $4 Million Portfolio (With Growth Potential In 2024)
November 02, 2023
In this blog post, we’re going to explore the world of dividend stocks and I’ll share my top five picks.
Via
Talk Markets
AbbVie Inc. (NYSE: ABBV) Highlighted for Surprising Price Action
October 30, 2023
Via
Investor Brand Network
AbbVie Unusual Options Activity
October 30, 2023
Via
Benzinga
2 No-Brainer Dividend Stocks to Buy This Week
October 30, 2023
These two top-income stocks are too cheap to ignore.
Via
The Motley Fool
Why AbbVie Stock Fell Today
October 27, 2023
AbbVie stock fell despite beating third-quarter expectations and raising its full-year outlook. Here's what investors need to know.
Via
The Motley Fool
Meet the Next Trillion-Dollar Companies: Our Top 3 Picks
November 02, 2023
Of the current five trillion-dollar companies, several more are within shouting distance. Here are our top three picks to get there.
Via
InvestorPlace
EXCLUSIVE: Roundhill Launches Dividend Kings ETF With 'The Gold Standard Of Dividend Growers,' Companies With 'Incredible Resilience'
November 02, 2023
A new ETF offers investors exposure to companies with long streaks of raising their dividends.
Via
Benzinga
Topics
ETFs
3 Dividend Stocks That Are Investor Safe Havens
November 02, 2023
If there is such a thing as safe dividend stocks, these three should be at the top of your list to consider.
Via
InvestorPlace
3 Dividend Stocks That Can Power Your Portfolio for Decades
November 02, 2023
From healthcare to home repair to tech, these stocks can help diversify your holdings.
Via
The Motley Fool
Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech
November 01, 2023
Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic.
Via
Talk Markets
Exposures
COVID-19
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?
November 01, 2023
Aldeyra Therapeutics stock is rising with heavy trading of ALDX shares after signing an exclusive option agreement with AbbVie.
Via
InvestorPlace
Pfizer Posted a Steep Loss. Is It Time to Sell?
November 01, 2023
A $5.6 billion inventory write-down isn't what investors wanted to see, but this company is made of many moving pieces.
Via
The Motley Fool
Investor patience tested as pharmaceutical stocks take a tumble
November 01, 2023
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector
Via
MarketBeat
10 Health Care Stocks Whale Activity In Today's Session
October 31, 2023
Via
Benzinga
Pfizer's Coming for AbbVie's Market Share. Here's What It Means for Investors
October 31, 2023
AbbVie has a head start, but that might not be enough to save its top line.
Via
The Motley Fool
Amgen Lifts Annual Outlook After Q3 Performance, But Stock Still Falls - Here's Why
October 31, 2023
Amgen Inc (NASDAQ: AMGN) reported Q3 FY23 sales of $6.90 billion, slightly missin
Via
Benzinga
J&J stock down as business unit mulls talc-related bankruptcy
October 31, 2023
Johnson & Johnson stock fell in the past week as talc-related lawsuits weigh on a subsidiary, which is mulling bankruptcy to mitigate payouts and settlements.
Via
MarketBeat
Topics
Bankruptcy
Lawsuit
Exposures
Financial
Legal
Is AbbVie Still a Good Dividend Stock to Buy?
October 31, 2023
The decline in sales of Humira, AbbVie's top seller, is enough to make anyone nervous.
Via
The Motley Fool
Why AbbVie Stock Was a Winner on Monday
October 30, 2023
One analyst tracking the pharmaceutical major upgraded his recommendation.
Via
The Motley Fool
AbbVie Analysts Increase Their Forecasts After Upbeat Earnings
October 30, 2023
AbbVie Inc (NYSE: ABBV) reported better-than-expected earnings for its third quarter and raised its profit outlook on Friday.
Via
Benzinga
AbbVie To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Monday
October 30, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
AbbVie Inc. Dividend Increase
October 28, 2023
AbbVie Inc. recently announced its next dividend of $1.55 per share, a 4.73% increase over the company's previous payout of $1.48.
Via
Talk Markets
AbbVie (ABBV) Q3 2023 Earnings Call Transcript
October 27, 2023
ABBV earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
FDA Gives Nod To Eli Lilly's First Treatment For Type Of Inflammatory Bowel Disease, To Compete With JNJ, Pfizer, AbbVie
October 27, 2023
The FDA approved Eli Lilly And Co's
Via
Benzinga
Exposures
Product Safety
AbbVie Raises Annual Profit Outlook As Newer Immunology Drugs Help Cushion Struggling Humira Sales
October 27, 2023
AbbVie Inc (NYSE: ABBV) has reported Q3 adjusted EPS of $2.95, down 19.4% Y/Y, beating the consensus of $2.88.
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
59
60
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.